 III. To determine rates of disease relapse, acute graft-versus-host disease GVHD, and day 100 disease-free survival in patients receiving 131 I-BC8 antibody Ab combined with CY, FLU, 2 Gy TBI, tacrolimus, MMF, and human leukocyte antigen HLA-haploidentical allogeneic hematopoietic cell transplant HCT. 